Heart Failure Drugs Market Research Report - Forecast till 2027

心不全薬市場:タイプ別情報(ベータ遮断薬、ACE阻害剤、アンジオテンシン受容体ネプリライシン阻害剤(ARNI)、アンジオテンシン受容体遮断薬(ARB)、利尿薬、その他)、エンドユーザー別(病院、専門センターなど)-2027年までの予測

ID: MRFR/HC/7288-CR | February 2020 | Region: Global | 104 Pages         

1 EXECUTIVE SUMMARY

1.1 OVERVIEW 13

1.1.1 MARKET SYNOPSIS 13

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 14

2.2 RESEARCH OBJECTIVE 14

2.3 LIST OF ASSUMPTIONS 14

3 RESEARCH METHODOLOGY

3.1 OVERVIEW 16

3.2 DATA MINING 16

3.3 SECONDARY RESEARCH 17

3.4 PRIMARY RESEARCH 18

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 19

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 20

3.6.1 BOTTOM-UP APPROACH 21

3.6.2 TOP-DOWN APPROACH 21

3.7 DATA TRIANGULATION 22

3.8 VALIDATION 22

4 MARKET DYNAMICS

4.1 OVERVIEW 23

4.2 DRIVERS 24

4.2.1 RISING CARDIOVASCULAR DISORDERS 24

4.2.2 LAUNCH OF SEVERAL HEART FAILURE DRUGS AND STRONG PIPELINE 24

4.2.3 RISING SALES OF ENTRESTO DRUG 25

4.2.4 DRIVERS IMPACT ANALYSIS 26

4.3 RESTRAINTS 26

4.3.1 SIDE-EFFECTS OF THE MEDICATION 26

4.3.2 RESTRAINTS IMPACT ANALYSIS 26

4.4 OPPORTUNITIES 27

4.4.1 EXPANDING DRUGS FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION (HF-PEF) 27

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 28

5.1.1 THREAT OF NEW ENTRANTS 28

5.1.2 BARGAINING POWER OF SUPPLIERS 29

5.1.3 THREAT OF SUBSTITUTES 29

5.1.4 BARGAINING POWER OF BUYERS 29

5.1.5 INTENSITY OF RIVALRY 29

5.2 VALUE CHAIN ANALYSIS 30

5.2.1 R&D AND DESIGNING 31

5.2.2 MANUFACTURING 31

5.2.3 DISTRIBUTION 31

5.2.4 MARKETING & SALES 31

5.2.5 POST-SALES MONITORING 31

6 HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

6.1 OVERVIEW 32

6.2 BETA-BLOCKERS 33

6.3 ACE INHIBITORS 34

6.4 ANGIOTENSIN-RECEPTOR NEPRILYSIN INHIBITORS (ARNI) 35

6.5 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS) 36

6.6 DIURETIC 36

6.7 OTHERS 37

7 HEART FAILURE DRUGS MARKET, BY END USER

7.1 OVERVIEW 38

7.2 HOSPITALS 39

7.3 SPECIALTY CENTERS 39

7.4 OTHERS 40

8 GLOBAL HEART FAILURE DRUGS MARKET, BY REGION

8.1 OVERVIEW 41

8.2 AMERICAS 42

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.2.1 NORTH AMERICA 44

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.2.1.1 US 45

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.2.1.2 CANADA 46

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.2.2 LATIN AMERICA 47

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3 EUROPE 48

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.1 WESTERN EUROPE 50

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.1.1 GERMANY 52

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.1.2 UK 53

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.1.3 FRANCE 54

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.1.4 ITALY 55

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.1.5 SPAIN 56

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.1.6 REST OF WESTERN EUROPE 57

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.3.2 EASTERN EUROPE 58

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.4 ASIA-PACIFIC 59

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.4.1 JAPAN 61

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.4.2 CHINA 62

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.4.3 INDIA 63

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.4.4 SOUTH KOREA 64

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.4.5 AUSTRALIA 65

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.4.6 REST OF ASIA PACIFIC 66

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.5 MIDDLE EAST & AFRICA 67

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.5.1 MIDDLE EAST 69

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

8.5.2 AFRICA 70

HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE

HEART FAILURE DRUGS MARKET, BY END USER

9 COMPETITIVE LANDSCAPE: GLOBAL HEART FAILURE DRUGS MARKET

9.1 OVERVIEW 71

9.2 COMPETITIVE ANALYSIS 71

9.3 COMPETITIVE BENCHMARKING 72

9.4 MAJOR GROWTH STRATEGY IN THE GLOBAL HEART FAILURE DRUGS MARKET 73

9.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 73

9.6 KEY DEVELOPMENTS AND GROWTH STRATEGIES 74

9.6.1 ACQUISITION 74

9.6.2 PRODUCT APPROVAL AND LAUNCH 74

9.6.3 COLLABORATION 75

9.7 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 75

9.7.1 SALES & OPERATING INCOME 75

9.7.2 R&D EXPENDITURE 76

10 COMPANY PROFILES

10.1 AMGEN INC. 77

10.1.1 COMPANY OVERVIEW 77

10.1.2 FINANCIAL OVERVIEW 77

10.1.3 PRODUCTS/SERVICES OFFERED 78

10.1.4 KEY DEVELOPMENT 78

10.1.5 SWOT ANALYSIS 78

10.1.6 KEY STRATEGIES 78

10.2 ASTRAZENECA 79

10.2.1 COMPANY OVERVIEW 79

10.2.2 FINANCIAL OVERVIEW 79

10.2.3 PRODUCTS/SERVICES OFFERED 80

10.2.4 ASTRAZENECA: KEY DEVELOPMENTS 80

10.2.5 SWOT ANALYSIS 81

10.2.6 KEY STRATEGIES 81

10.3 NOVARTIS AG 82

10.3.1 COMPANY OVERVIEW 82

10.3.2 FINANCIAL OVERVIEW 82

10.3.3 PRODUCTS/SERVICES OFFERED 83

10.3.4 KEY DEVELOPMENTS 83

10.3.5 SWOT ANALYSIS 83

10.3.6 KEY STRATEGIES 84

10.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 85

10.4.1 COMPANY OVERVIEW 85

10.4.2 FINANCIAL OVERVIEW 85

10.4.3 PRODUCTS/SERVICES OFFERED 86

10.4.4 KEY DEVELOPMENTS 86

10.4.5 SWOT ANALYSIS 86

10.4.6 KEY STRATEGIES 86

10.5 BAYER AG 87

10.5.1 COMPANY OVERVIEW 87

10.5.2 FINANCIAL OVERVIEW 87

10.5.3 PRODUCTS/SERVICES OFFERED 88

10.5.4 KEY DEVELOPMENTS 88

10.5.5 SWOT ANALYSIS 88

10.5.6 KEY STRATEGIES 89

10.6 JOHNSON & JOHNSON SERVICES, INC. 90

10.6.1 COMPANY OVERVIEW 90

10.6.2 FINANCIAL OVERVIEW 90

10.6.3 PRODUCTS/SERVICES OFFERED 91

10.6.4 KEY DEVELOPMENTS 91

10.6.5 SWOT ANALYSIS 91

10.6.6 KEY STRATEGIES 92

10.7 BRISTOL-MYERS SQUIBB COMPANY 93

10.7.1 COMPANY OVERVIEW 93

10.7.2 FINANCIAL OVERVIEW 93

10.7.3 PRODUCTS/SERVICES OFFERED 94

10.7.4 KEY DEVELOPMENTS 94

10.7.5 SWOT ANALYSIS 95

10.7.6 KEY STRATEGIES 95

10.8 MERCK SHARP & DOHME CORP. 96

10.8.1 COMPANY OVERVIEW 96

10.8.2 FINANCIAL OVERVIEW 96

10.8.3 PRODUCTS/SERVICES OFFERED 97

10.8.4 KEY DEVELOPMENTS 97

10.8.5 SWOT ANALYSIS 97

10.8.6 KEY STRATEGIES 98

10.9 PFIZER, INC. 99

10.9.1 COMPANY OVERVIEW 99

10.9.2 FINANCIAL OVERVIEW 99

10.9.3 PRODUCTS/SERVICES OFFERED 100

10.9.4 KEY DEVELOPMENTS 100

10.9.5 SWOT ANALYSIS 100

10.9.6 KEY STRATEGIES 101

10.10 GILEAD SCIENCES, INC. 102

10.10.1 COMPANY OVERVIEW 102

10.10.2 FINANCIAL OVERVIEW 102

10.10.3 PRODUCTS/SERVICES OFFERED 103

10.10.4 KEY DEVELOPMENTS 103

10.10.5 SWOT ANALYSIS 103

10.10.6 KEY STRATEGIES 103

11 APPENDIX

11.1 REFERENCES 104

11.2 RELATED REPORTS 104

12 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 14

TABLE 2 GLOBAL HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 33

TABLE 3 GLOBAL HEART FAILURE DRUGS MARKET FOR BETA-BLOCKERS, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 4 GLOBAL HEART FAILURE DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 5 GLOBAL HEART FAILURE DRUGS MARKET FOR ANGIOTENSIN-RECEPTOR NEPRILYSIN INHIBITORS (ARNI), BY REGION,

2020–2027 (USD MILLION) 35

TABLE 6 GLOBAL HEART FAILURE DRUGS MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), BY REGION,

2020–2027 (USD MILLION) 36

TABLE 7 GLOBAL HEART FAILURE DRUGS MARKET FOR DIURETIC, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 8 GLOBAL HEART FAILURE DRUGS MARKET FOR OTHERS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 9 GLOBAL HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 38

TABLE 10 GLOBAL HEART FAILURE DRUGS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 11 GLOBAL HEART FAILURE DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 12 GLOBAL HEART FAILURE DRUGS MARKET FOR OTHERS, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 13 GLOBAL HEART FAILURE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 14 AMERICAS: HEART FAILURE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 15 AMERICAS: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 43

TABLE 16 AMERICAS: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 43

TABLE 17 NORTH AMERICA: HEART FAILURE DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 44

TABLE 18 NORTH AMERICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 44

TABLE 19 NORTH AMERICA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 45

TABLE 20 US: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 45

TABLE 21 US: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 45

TABLE 22 CANADA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 46

TABLE 23 CANADA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 46

TABLE 24 LATIN AMERICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 47

TABLE 25 LATIN AMERICA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 47

TABLE 26 EUROPE: HEART FAILURE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 27 EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 49

TABLE 28 EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 49

TABLE 29 WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 50

TABLE 30 WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 31 WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 51

TABLE 32 GERMANY: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 33 GERMANY: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 52

TABLE 34 UK: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 35 UK: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 53

TABLE 36 FRANCE: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 37 FRANCE: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 54

TABLE 38 ITALY: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 39 ITALY: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 55

TABLE 40 SPAIN: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 41 SPAIN: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 56

TABLE 42 REST OF WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 43 REST OF WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 57

TABLE 44 EASTERN EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 45 EASTERN EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 58

TABLE 46 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59

TABLE 47 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 48 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 49 JAPAN: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 50 JAPAN: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 61

TABLE 51 CHINA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 52 CHINA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 62

TABLE 53 INDIA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 54 INDIA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 55 SOUTH KOREA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 56 SOUTH KOREA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 64

TABLE 57 AUSTRALIA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 58 AUSTRALIA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 59 REST OF ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 60 REST OF ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 66

TABLE 61 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 67

TABLE 62 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 63 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 64 MIDDLE EAST: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 65 MIDDLE EAST: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 66 AFRICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 67 AFRICA: HEART FAILURE DRUGS MARKET, BY END USER, 2020–2027 (USD MILLION) 70

TABLE 68 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE HEART FAILURE DRUGS MARKET 73

TABLE 69 ACQUISITION: GLOBAL HEART FAILURE DRUGS MARKET 74

TABLE 70 PRODUCT APPROVAL AND LAUNCH: GLOBAL HEART FAILURE DRUGS MARKET 74

TABLE 71 COLLABORATION: GLOBAL HEART FAILURE DRUGS MARKET 75

TABLE 72 AMGEN INC.: PRODUCTS/SERVICES OFFERED 78

TABLE 73 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 80

TABLE 74 KEY DEVELOPMENTS 80

TABLE 75 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 83

TABLE 76 KEY DEVELOPMENTS 83

TABLE 77 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES OFFERED 86

TABLE 78 BAYER AG: PRODUCTS/SERVICES OFFERED 88

TABLE 79 BAYER AG: KEY DEVELOPMENTS 88

TABLE 80 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED 91

TABLE 81 JOHNSON & JOHNSON SERVICES, INC: KEY DEVELOPMENTS 91

TABLE 82 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED 94

TABLE 83 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS 94

TABLE 84 MERCK SHARP & DOHME CORP.: PRODUCTS/SERVICES OFFERED 97

TABLE 85 PFIZER, INC.: PRODUCTS/SERVICES OFFERED 100

TABLE 86 PFIZER, INC.: KEY DEVELOPMENTS 100

TABLE 87 GILEAD SCIENCES, INC.: PRODUCTS/SERVICES OFFERED 103

13 LIST OF FIGURES

FIGURE 1 GLOBAL HEART FAILURE DRUGS MARKET STRUCTURE 15

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 20

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL HEART FAILURE DRUGS MARKET 23

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL HEART FAILURE DRUGS MARKET 28

FIGURE 5 VALUE CHAIN ANALYSIS OF THE GLOBAL HEART FAILURE DRUGS MARKET 30

FIGURE 6 GLOBAL HEART FAILURE DRUGS MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 32

FIGURE 7 GLOBAL HEART FAILURE DRUGS MARKET, BY END USER, 2020 & 2027 (USD MILLION) 38

FIGURE 8 GLOBAL HEART FAILURE DRUGS MARKET, BY REGION, 2020 & 2027 (USD MILLION) 41

FIGURE 9 AMERICAS: HEART FAILURE DRUGS MARKET SHARE, BY REGION 2020 (%) 42

FIGURE 10 NORTH AMERICA: HEART FAILURE DRUGS MARKET SHARE, BY COUNTRY 2020 (%) 44

FIGURE 11 EUROPE: HEART FAILURE DRUGS MARKET SHARE, BY REGION 2020 (%) 48

FIGURE 12 WESTERN EUROPE: HEART FAILURE DRUGS MARKET SHARE, BY COUNTRY 2020 (%) 50

FIGURE 13 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET SHARE, BY COUNTRY 2020 (%) 59

FIGURE 14 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET SHARE, BY REGION 2020 (%) 67

FIGURE 15 BENCHMARKING OF MAJOR COMPETITORS 72

FIGURE 16 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL HEART FAILURE DRUGS MARKET 73

FIGURE 17 HEART FAILURE DRUGS MARKET, COMPETITIVE LANDSCAPE (% SHARE) 74

FIGURE 18 SALES & OPERATING INCOME 2020 75

FIGURE 19 MAJOR PLAYERS R&D EXPENDITURE 2020 76

FIGURE 20 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 77

FIGURE 21 AMGEN INC.: SWOT ANALYSIS 78

FIGURE 22 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 79

FIGURE 23 ASTRAZENECA: SWOT ANALYSIS 81

FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 82

FIGURE 25 NOVARTIS AG: SWOT ANALYSIS 83

FIGURE 26 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT 85

FIGURE 27 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS 86

FIGURE 28 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 87

FIGURE 29 BAYER AG: SWOT ANALYSIS 88

FIGURE 30 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 90

FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 91

FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT 93

FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS 95

FIGURE 34 MERCK SHARP & DOHME CORP.: FINANCIAL OVERVIEW SNAPSHOT 96

FIGURE 35 MERCK SHARP & DOHME CORP.: SWOT ANALYSIS 97

FIGURE 36 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT 99

FIGURE 37 PFIZER, INC.: SWOT ANALYSIS 100

FIGURE 38 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT 102

FIGURE 39 GILEAD SCIENCES, INC.: SWOT ANALYSIS 103

心不全薬市場

心不全治療薬市場は、2022年から2030年の予測期間から5.9%のCAGRで1810億米ドルに達すると予測されています。

セグメンテーション

タイプ別 Beta Blockers Ace Inhibitors Angiotensin Receptor Neprilysin Inhibitors Angiotensin Receptor Blockers Diuretic
By End User Hospitals Specialty Centers

キープレーヤー

  • Amgen Inc. (US)
  • AstraZeneca (UK)
  • Novartis AG (Switzerland)
  • Boehringer Ingelheim International GmbH (Germany)
  • Johnson & Johnson Services
  • Inc. (UK)
  • Bristol-Myers Squibb Company (US)

運転手

  • Rising Cardiovascular Disorders
  • Launch of Several Heart Failure Drugs
Speak to Analyst Request a Free Sample

心不全薬市場の概要:


心不全薬の市場規模は、2025年までに17.79%のCAGRを記録し、13,069.75万米ドルに達すると予想されています。心不全疾患は、製薬会社がより良い治療オプションを追求する動機となっています。これは、世界的に検出率がますます高まっているため、製薬会社が処方する製品がこの増加する市場で好評を博しているためです。


新型コロナウイルス分析


COVID-19は、過去1年間で心臓病を死亡の第一の原因として通過しました。この事実により、いくつかの製薬会社は心不全に対抗するための革新的で独創的なソリューションを試すようになりました。たとえば、Modernaからの注射とファイザーとBioNTechのコラボレーションでは、メッセンジャーRNAと呼ばれる遺伝物質を使用して、体の細胞を効率的にワクチン工場に変えます。決して、この戦術は臨床実験以外で使用されていなかったため、コロナウイルスに対する成功を見て、最も熱心な支持者の一部でさえ驚かせました。この開発は、mRNA企業が心不全治療、インフルエンザワクチン、嚢胞性線維症、そしておそらくHIVのための技術を利用する拍車をかけると推定されています。


マーケットダイナミクス


ドライバー


上昇する心血管障害


心臓病の警戒心の急増は、今後の心不全薬の市場規模の発展のための豊富な機会を生み出すと推定されています。


いくつかの心不全治療薬の発売


心不全の病気に対処するために継続的に発売されている強力な医薬品のパイプラインの存在は、差し迫った期間の市場の成長を導くと推定されています。


機会


駆出率を維持した心不全治療薬の拡大


保存駆出率心不全を効果的な薬で治療することを目的とした強化された研究は、心不全薬市場を促進する可能性があります。


チャレンジ


薬の副作用


重篤な副作用の発生の増加は、心不全薬市場を制限すると推定されています。


セグメントの概要


タイプ別


ACEインヒビターセグメントは、予測期間の期間中に市場を操縦する可能性があります。


エンドユーザー別


病院セグメントは、これらの施設で実施されることが多い徹底的な診断の後に処方されることが多いため、支配的な利害関係があると予測されています。


地域分析


上昇した事件に拍車をかけるアメリカ大陸地域


アメリカ大陸の地域市場は、心不全薬の主要市場でした。南北アメリカの心不全治療薬市場の成長は、心血管障害の有病率の上昇、医療費の増加、および肥満症例の激化によるものです。その上、過度のアルコール摂取、有害な食生活など、絶えず変化する生活習慣肥満、および身体活動の欠如は、個人を不整脈や心不全に対してより脆弱にし、したがって地域市場の成長を促進します。


欧州地域、新薬の承認を得て開発を模索


ヨーロッパは心不全薬の次の主要市場です。心血管障害の増加と喫煙人口の増加により、予測期間を通じてプラスの開発率を記録すると予想されます。また、欧州連合で増加する高齢者人口は、欧州地域の心不全薬市場を説得しています。


APAC、自信ある開発を見せる


アジア太平洋地域は、患者プールの増加と技術開発の拡大により、予測期間中に市場で最も高い成長能力を示すと予測されています。APAC地域の急速な発展は、一人当たりの総所得と医療価値を高めるための政府の提案によるものであり、心血管疾患の増加は、地域全体の発展を後押しするでしょう。


競争環境


世界の心不全治療薬市場の著名なプレーヤーは次のとおりです



  • Amgen Inc. (米国)

  • アストラゼネカ (英国)

  • ノバルティスAG(スイス)、

  • ベーリンガーインゲルハイムインターナショナル GmbH (ドイツ),

  • ジョンソン・エンド・ジョンソン・サービス・インク(英国)

  • ブリストル・マイヤーズスクイブ社 (米国)

  • メルク・シャープ・アンド・ドーム・コーポレーション(米国)

  • ファイザー社 (米国)

  • ギリアド・サイエンシズ社 (カリフォルニア)


最近の動向


2021年1月2つの新しい研究によると、例外的な糖尿病薬は、最近心不全または腎臓病を悪化させている糖尿病患者に心臓関連の利益を示しています。ソタグリフロジン(Zynquista)という薬は、腎臓が尿中により多くの糖を放出するSGLT2阻害剤のクラスに属します。この薬はSGLT1阻害剤でもあり、腸内の糖同化を減少させます。このデュアルアクションは、糖尿病の印である高血糖を下げます。腎臓病の人では、ソタグリフロジンは、プラセボと比較して、心血管疾患および入院および心不全の緊急訪問による死亡の総数を約26%減少させました。


2021年1月バイエルとメルク&カンパニーの心不全治療薬vericiguatは、次第に競争の激しい市場で、Verquvoというブランド名でFDAによって承認されました。Verquvoは、症候性慢性心不全および駆出率が45%未満の成人における心血管死および心不全入院のリスクを軽減することが承認されています。この薬は、心不全のために入院した後、または静脈内利尿薬を必要としている患者に摂取することができます。しかし、この薬は、ノバルティスとアストラゼネカが覇権をめぐって競争が激化する市場に参入しています。エントレスト(sacubitril+valsartan)は、5年前に駆出率が低下した患者でFDA承認を受けた。


2021年1月科学者たちは、標準的な化学療法薬であるドキソルビシンが心臓の損傷を防ぐのに不可欠であることを発見しました。この薬剤は、多くの種類の固形腫瘍および血液癌の治療に使用され、投与プロセスは、薬物を血液から心臓細胞に移動させるトランスポーターとして機能する特定の種類のタンパク質をヒッチハイクすることによって心臓細胞に侵入することができる。別の抗がん剤を導入することで



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 13,069.75 Million
  CAGR   17.79% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (UK), Bristol-Myers Squibb Company (US), Merck Sharp & Dohme Corp. (US), Pfizer, Inc. (US), and Gilead Sciences, Inc. (California)
  Key Market Opportunities   Expanding Drugs for Heart Failure With Preserved Ejection Fraction
  Key Market Drivers

  • Rising Cardiovascular Disorders
  • Launch of Several Heart Failure Drugs


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Global heart failure drugs market is estimated to hold a market value of USD13,069.75 million by the end of 2025.

    Global heart failure drugs market is estimated to expand at a CAGR of 17.79% by the end of 2025.

    Global heart failure drugs market can be segmented on the basis of end-user, type, and region.

    The APAC region is estimated to acquire the highest market growth during the forecast period.

    Boehringer Ingelheim International GmbH (Germany), Merck Sharp & Dohme Corp. (US), Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (California), and a few more are some of the key players of the global heart failure drugs market.